Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer
- 126 Downloads
The outcomes of three-dimensional conformal radiation therapy (3D-CRT) combined with neoadjuvant hormonal therapy (NAHT) in Japanese patients with locally advanced prostate cancer who initiated salvage hormonal therapy (SHT) at a relatively early phase were evaluated.
Between April 1998 and April 2003, 70 Japanese patients with T3N0M0 prostate cancer who received radical 3D-CRT treatment were evaluated. The median age, initial prostate-specific antigen (PSA) level, and duration of NAHT were 73 years old, 26.3 ng/ml, and 4 months, respectively. Seventy grays were given in 35 fractions that were confined to the prostate and seminal vesicles. Adjuvant hormonal therapy was not administered after 3D-CRT in any of the cases.
The median follow-up period was 64.9 months. The median PSA value at the time of initiation of SHT was 5.0 ng/ml (range 0.1–21.6 ng/ml). Overall, disease-specific, PSA failure-free (based on the Phoenix definition) and SHT-free survival rates at 5 years were 90.3% (95% CI 86.5–94.0), 96.5% (94.0–98.9), 60.5% (48.2–72.7), and 63.5% (57.2–69.8), respectively. Therefore, two-thirds of the patients were still hormone-free at 5 years.
PSA control rates in our series of Japanese patients with stage T3N0M0 prostate cancer treated with the standard dose of 3D-CRT combined with NAHT seemed higher than expected. This approach involving 3D-CRT combined with NAHT with the initiation of SHT at PSA values of around 5 ng/ml may be one option for Japanese patients with locally advanced prostate cancer, although further prospective study is required to confirm the validity.
KeywordsProstate cancer Neoadjuvant hormonal therapy Three-dimensional conformal radiation therapy PSA failure Salvage hormonal therapy
This work was partially supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (20229009).
Conflict of interest statement
Authors have no conflicts of interest.
- 3.Japanese Ministry of Health, Labour and Welfare (2005) The number and rate of death. http://www.dbtk.mhlw.go.jp/toukei/youran/data18k/1-27.xls
- 4.Japanese Ministry of Health, Labour and Welfare (2005) The number and rate of death by malignancy. http://www.dbtk.mhlw.go.jp/toukei/youran/data18k/1-31.xls
- 5.Ohshima A, Kuroishi T, Tashima K et al (2004) Cancer morbidity/mortality/prognosis, 2004. Shinohara, TokyoGoogle Scholar
- 6.Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61Google Scholar
- 8.Pilepich MV, Winter K, John MJ et al (2001) Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252Google Scholar
- 9.Kumar S, Shelley M, Harrison C et al (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev CD006019Google Scholar
- 18.Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974Google Scholar
- 20.Pilepich MV, Caplan R, Byhardt RW et al (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013–1021Google Scholar
- 21.Hanks GE, Pajak TF, Porter A et al (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972–3978Google Scholar
- 22.Crook J, Ludgate C, Malone S et al (2004) Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60:15–23PubMedCrossRefGoogle Scholar
- 26.National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology prostate cancer V.I.2010. http://www.nccn.org/
- 27.National Cancer Institute (2010) Prostate cancer treatment (PDQ®). http://www.cancer.gov/
- 28.Japanese Ministry of Health, Labour and Welfare (2005) The 20th life tables. http://www.mhlw.go.jp/english/database/db-hw/lifetb20th/table-m.html
- 29.Denham JW, Steigler A, Lamb DS et al (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841–850Google Scholar
- 31.Pilepich MV, Krall JM, al-Sarraf M et al (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616–623Google Scholar
- 32.Roach M 3rd, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911Google Scholar
- 33.Shipley WU, Desilvio M, Pilepich MV et al (2006) Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG Protocol 86-10. Int J Radiat Oncol Biol Phys 64:1162–1167Google Scholar